Miglietta, F., Dieci, M. V., Tsvetkova, V., Griguolo, G., Vernaci, G., Menichetti, A., . . . Guarneri, V. (2020). Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer. Oncologist.
Chicago-stil citatMiglietta, Federica, et al. "Validation of Residual Proliferative Cancer Burden As a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients With Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer." Oncologist 2020.
MLA-referensMiglietta, Federica, et al. "Validation of Residual Proliferative Cancer Burden As a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients With Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer." Oncologist 2020.